Walleye Capital’s Standard BioTools LAB Stock Holding History

Walleye Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-561,521	Closed	-$994K	–	5603
2024 Q2	$994K	Buy	+561,521	New	+$1.37M	﹤0.01%	2856
2023 Q3	–	Sell	-20,535	Closed	-$39.6K	–	5122
2023 Q2	$39.6K	Buy	+20,535	New	+$40.5K	﹤0.01%	3682
2022 Q3	–	Sell	-17,468	Closed	-$28K	–	3398
2022 Q2	$28K	Buy	+17,468	New	+$43.2K	﹤0.01%	1869
2020 Q3	–	Sell	-11,093	Closed	-$44K	–	909
2020 Q2	$44K	Sell	11,093 -159,409	-93%	-$555K	0.01%	548
2020 Q1	$433K	Buy	170,502 +42,416	+33%	+$139K	0.1%	256
2019 Q4	$446K	Buy	+128,086	New	+$451K	0.03%	728
2019 Q2	–	Sell	-14,700	Closed	-$195K	–	1897
2019 Q1	$195K	Buy	+14,700	New	+$155K	0.03%	792

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's LAB Position: Q3 2024 in Review

Walleye Capital sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 561,521 shares — an estimated $994K sold.

Walleye Capital first reported a position in LAB in Q1 2019 and held it in 7 quarters. The position peaked at $994K in Q2 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

Walleye Capital reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 561,521 Standard BioTools shares in Q3 2024, an estimated $994K.
Walleye Capital first reported a position in Standard BioTools in Q1 2019 and held it in 7 quarters.
Walleye Capital's Standard BioTools position peaked at $994K in Q2 2024.
141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.